FREE SURVIVAL PFS
Prognostic role of pretreatment serum albumin in renal cell carcinoma: a systematic review and meta-analysis
... or survival or ...overall survival (OS), cancer-specific survival (CSS), disease-free survival (DFS), and progression- free survival (PFS) were the frequently used ...
10
Yttrium-90 resin microspheres as an adjunct to sorafenib in patients with unresectable hepatocellular carcinoma
... overall survival (OS) and progression-free survival (PFS) as well as hepatic and extrahepatic disease PFS and incidence of adverse ...
7
Prognostic utility of baseline neutrophil-to-lymphocyte ratio in patients receiving immune checkpoint inhibitors: a review and meta-analysis
... overall survival (OS) (HR, 1.92; 95% CI, 1.29–2.87; p=0.001) and progression-free survival (PFS; HR, ...and PFS (OS: HR, 1.82; 95% CI, 1.29–2.87; p=0.001 and PFS: HR, ...and ...
11
<p>Drug-Related Hypertension Associated with the Efficacy of Apatinib on Hepatocellular Carcinoma</p>
... overall survival (OS), progression-free survival (PFS), Time to Progression (TTP) and disease control rate (DCR) in patients with apatinib treatment, and assessed the safety according to the ...
11
Molecular heterogeneity assessment by next-generation sequencing and response to gefitinib of EGFR mutant advanced lung adenocarcinoma
... Progression-Free Survival, PFS) with: 1) the proportion of cells carrying the EGFR mutation, calculated on the basis of the value of the proportion of mutated alleles (PMA) that is derived from NGS ...
13
<p>Programmed Cell Death Protein-1 (PD-1)-Targeted Immunotherapy for Advanced Hepatocellular Carcinoma in Real World</p>
... one-year survival rate was ...overall survival (OS) of 15 months (95% CI: ...progression-free survival (PFS) was 10 months (95% CI: ...Median PFS for patients with partial ...
7
Lactate dehydrogenase is a prognostic indicator in patients with hepatocellular carcinoma treated by sorafenib: results from the real life practice in HBV endemic area
... Results: The cut-off value was 221 U/L. With a median follow up of 15 (range, 3-73) months, 91 patients reached the endpoint. Multivariate analysis proved that pre- treatment serum LDH level was an independent prognostic ...
18
Observational cohort study focused on treatment continuity of patients administered XELOX plus bevacizumab for previously untreated metastatic colorectal cancer
... Background: There has been remarkable progress in systemic chemotherapy for metastatic colorectal cancer due to the widespread use of irinotecan, oxaliplatin, anti-vascular endothelial growth factor antibody, and ...
8
Systemic chemotherapy plus cetuximab after complete surgery in the treatment of isolated colorectal peritoneal carcinoma: COCHISE phase II clinical trial
... progression-free survival (PFS) of ...progression-free survival (PFS) and overall survival (OS) rates for CRPC treated by CCS without ...
6
Panitumumab plus FOLFIRI vs. Bevacizumab plus FOLFIRI for First Line Treatment of Metastatic Colorectal Cancer with Wild-Type KRAS Tumors; a retrospective study.
... overall survival (OS), progression-free survival (PFS), as well as response rate (RR), in patients with previously untreated metastatic colorectal cancer ...OS, PFS, and RR when ...
7
Original Article Prognostic significance of CD4/CD8 ratio in patients with breast cancer
... and survival rates were analyzed by the Kaplan-Meier method, log-rank test and multivariate Cox proportional hazards ...metastasis-free survival (DMFS, P<0.001) and progression-free ...
7
Nadir CA-125 level as prognosis indicator of high-grade serous ovarian cancer
... Overall survival (OS) is defined as the time interval from diagnosis until death, or until last follow-up examination of patients who are still ...Progression free survival (PFS) is the length ...
8
Pazopanib in advanced desmoplastic small round cell tumours: a multi-institutional experience
... induce the upregulation of PDGF ligand and receptor, which might be responsible for the prominent tumor- associated desmoplasia detected in this disease [18-20]. On this bases, imatinib activity was tested in two phase ...
6
Abstract Background and Objectives: ovarian cancer comprise 4% of all women cancer and 34% amongst
... progression-free survival (PFS) to detection of progression of disease or death with number of hospital stay peri-operative and postoperative ...
6
Use of carfilzomib in second-line therapy and beyond for relapsed multiple myeloma
... lenalidomide 25 mg/day and dexamethasone 40 mg. The overall response rate in the experimental arm was 87% as compared to 67% in the control arm, and the likelihood of achieving a VGPR or better was 70% vs 40%. The median ...
8
QTWiST analysis of the RECOURSE trial of trifluridine/tipiracil in metastatic colorectal cancer
... The QTWiST improvement with trifluridine/tipiracil in the RECOURSE trial was 1.5 months out of an OS differ- ence of 1.8 months. Thus, by these criteria, trifluridine/ tipiracil clearly confers a clinically meaningful ...
6
Advances in T-cell checkpoint immunotherapy for head and neck squamous cell carcinoma
... their proper activation, two sets of signals are required from antigen presenting cells (APCs) regulating T-cell survival, proliferation, and immune response in the lymph node. In a normally functioning immune ...
10
Prognostic and predictive value of EGFR in head and neck squamous cell carcinoma
... significant survival improvement was observed in EGFR positive unresectable HNSCC patients treated with this inhibitor and RT compared to control patients receiving placebo and RT ...
18
Dynamic Contrast Enhanced MR Imaging of Nonenhancing T2 High Signal Intensity Lesions in Baseline and Posttreatment Glioblastoma: Temporal Change and Prognostic Value
... The present study had a few limitations. First, the retrospective study design had potential selection bias. To minimize the selection bias, we attempted to include all consecutive patients diagnosed with glioblastoma ...
8
The combination of vemurafenib and cobimetinib in advanced melanoma
... vemurafenib/cobimetinib (combination) or vemurafenib/placebo (control) in the first line setting. The combination group had a significantly improved median PFS of 9.9months compared to 6.2 months, with HR of 0.51 ...
28